MEREO BIOPHARMA GROUP PLC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
MEREO BIOPHARMA GROUP PLC (MREO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$10.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$4.61M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$8.23M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$8.69M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$9.67M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$30.66M, a 343.09% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $12.61M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$13.58M.
- MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$46.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.65M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$4.61M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$30.66M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$23.02M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$16.01M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$8.23M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $12.61M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $22.07M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $30.19M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$8.69M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$13.58M 10-K · filed 2024-03-27 | |||
| 2023-06-30 | -$17.35M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$9.67M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$46.63M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |